Absci's core business segment focuses on leveraging its proprietary generative AI platform to discover and develop novel biologic therapeutics. This involves research and development activities centered around designing and validating new drug candidates, including antibodies and other protein-based therapeutics. The company utilizes advanced technologies such as machine learning and synthetic biology to accelerate the drug discovery process. Therapeutic areas of focus include oncology and other areas with high unmet medical needs. The patient impact is realized through the potential for more effective and targeted treatments. Absci's market positioning is based on its unique AI-driven approach, offering a competitive advantage in speed and efficiency. Future opportunities include expanding into new therapeutic areas and forming strategic partnerships. Regulatory and clinical aspects are addressed through clinical trials and seeking FDA approval for drug candidates. Partnerships with companies like AstraZeneca and Memorial Sloan Kettering Cancer Center are key to advancing this segment.

This segment focuses on developing high-performing production cell lines for the manufacturing of biologic drugs. Absci's integrated platform streamlines the cell line development process, enabling faster and more efficient production of therapeutic proteins. The company utilizes advanced genetic engineering and cell culture techniques. This segment supports the development of therapeutics across various therapeutic areas. The patient impact is improved through the availability of high-quality, cost-effective biologics. Absci's market position is enhanced by its ability to provide optimized cell lines, which is a critical component of drug manufacturing. Future opportunities include expanding cell line development capabilities and partnering with pharmaceutical companies to support their manufacturing needs. Regulatory and clinical aspects are addressed through adherence to GMP standards and collaboration with regulatory agencies. This segment is crucial for supporting the commercialization of Absci's drug candidates and those of its partners.